The antiemetic activity of droperidol administered by intramuscular injection during cisplatin chemotherapy: a pilot study.
The antiemetic activity of escalating doses of droperidol was evaluated in ten patients undergoing chemotherapy with cisplatin regimens. Major antiemetic activity was achieved in five patients, two patients had less nausea and vomiting as compared with prior prochlorperazine therapy, and three patients were refractory to droperidol. No dose-response relationship was observed. Sedation occurred in nine patients, and two patients experienced dystonic reactions. Droperidol is a relatively safe and effective antiemetic for patients undergoing chemotherapy with cisplatin.
D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000009:adverse effects*; D004329:Droperidol / Q000008:administration & dosage / Q000627:therapeutic use*; D004407:Dysgerminoma / Q000188:drug therapy; D006801:Humans; D007273:Injections, Intramuscular; D008875:Middle Aged; D010865:Pilot Projects; D011346:Prochlorperazine / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D004329:Droperidol; D002945:Cisplatin; D011346:Prochlorperazine